DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Virtual Event

2024 年 09 月 24 日 1:00 下午 - 2024 年 09 月 26 日 5:30 下午

(Central Europe Standard Time)

4051 Basel, Switzerland

EU Risk Management Plan Creation

This practical virtual live training course will teach the EU RMP creation skills from both industry and regulatory perspective, including the project management, medical writing, design, and maintenance of the document. It also includes preview of the GVP V Rev 3 and RMP Template Rev 3.

讲师团队

Emil Andrei  Cochino, MD, MHS

Emil Andrei Cochino, MD, MHS

Scientific Senior Specialist (Risk Management), European Medicines Agency, Netherlands

Dr Emil Andrei Cochino is a Specialist in Public Health and Health Services Management. He has been a scientific officer at EMA from 2009, and is working in the Human Medicines Department as a Scientific Senior Specialist (Risk Management), where he is responsible for peer-reviewing risk management plans for Advanced Therapy Medicinal Products. Furthermore, he is overseeing the revision 3 update of GVP Module V – Risk Management Systems and is coordinating the Agency’s transparency efforts for RMPs.

Maria  Escudeiro dos Santos

Maria Escudeiro dos Santos

Risk Management Specialist, European Medicines Agency, Netherlands

Maria Santos has a Pharmaceutical Sciences master degree. She has joined the EMA in 2018 and is working in the Human Medicines Department as a Product Lead and Risk Management Specialist in the Vaccines and Therapies for Infectious Diseases office while collaborating with the revision 3 update of GVP Module V – Risk Management Systems.

Klaudija  Marijanovic Barac, MD

Klaudija Marijanovic Barac, MD

Senior Director, Teva Periodic Reports and Risk Management Centre, Teva, Croatia (Hrvatska)

Klaudija is a physician with more than 20 years of experience in different pharmacovigilance fields. At present, she is Head of TPC – unit responsible for Company Core Safety Information, aggregate reports and risk management worldwide, supporting marketing authorizations and safety strategy for generics, biosimilar and innovative Teva products. Klaudija led in-house development of additional risk minimisation (ARM) implementation tracking tool and ARM digitalisation. Klaudija is Co-Chair of the Pharmacovigilance Working Group in Medicines for Europe.

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。